Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13330959 | 0.81 | MEN1 (0.34) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL4615191 | 0.81 | MEN1 (0.34) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL7917188 | 0.76 | MEN1 (0.36) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL6886964 | 0.76 | MEN1 (0.36) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL6884524 | 0.75 | MEN1 (0.35) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL6888536 | 0.74 | CTSL (0.35) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL6888405 | 0.71 | CTSL (0.34) | MEN1MAPK1KMT2ACTSKCTSS | |
| SCHEMBL8090691 | 0.69 | HDAC4 (0.38) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL15068266 | 0.69 | MEN1 (0.35) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL2630592 | 0.69 | KMT2A (0.42) | MEN1MAPK1KMT2AHDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2010-05-06 | — | — | US | disclosed |
| US-20100041728-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | MEDIVIR AB | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041728-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | COPB1, HAVCR2, NOD1 | MEN1 4343/4885MAPK1 516/4885KMT2A 4465/4885 |
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | NUDT1, PNP, SLC28A1 | MEN1 4587/4885MAPK1 912/4885KMT2A 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.